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A B S T R A C T
Many skeletal tissue regenerative strategies centre around the multifunctional properties of bone marrow de-
rived stromal cells (BMSC) or mesenchymal stem/stromal cells (MSC)/bone marrow derived skeletal stem cells
(SSC). Specific identification of these particular stem cells has been inconclusive. However, enriching these
heterogeneous bone marrow cell populations with characterised skeletal progenitor markers has been a con-
tributing factor in successful skeletal bone regeneration and repair strategies. In the current studies we have
isolated, characterised and enriched ovine bone marrow mesenchymal stromal cells (oBMSCs) using a specific
antibody, Stro-4, examined their multipotential differentiation capacity and, in translational studies combined
Stro-4+ oBMSCs with a bovine extracellular matrix (bECM) hydrogel and a biocompatible melt electro-written
medical-grade polycaprolactone scaffold, and tested their bone regenerative capacity in a small in vivo, highly
vascularised, chick chorioallantoic membrane (CAM) model and a preclinical, critical-sized ovine segmental
tibial defect model.
Proliferation rates and CFU-F formation were similar between unselected and Stro-4+ oBMSCs. Col1A1,
Col2A1, mSOX-9, PPARG gene expression were upregulated in respective osteogenic, chondrogenic and adipo-
genic culture conditions compared to basal conditions with no significant difference between Stro-4+ and
unselected oBMSCs. In contrast, proteoglycan expression, alkaline phosphatase activity and adipogenesis were
significantly upregulated in the Stro-4+ cells. Furthermore, with extended cultures, the oBMSCs had a predis-
position to maintain a strong chondrogenic phenotype. In the CAM model Stro-4+ oBMSCs/bECM hydrogel was
able to induce bone formation at a femur fracture site compared to bECM hydrogel and control blank defect
alone. Translational studies in a critical-sized ovine tibial defect showed autograft samples contained sig-
nificantly more bone, (4250.63 mm3, SD = 1485.57) than blank (1045.29 mm3, SD = 219.68) ECM-hydrogel
(1152.58 mm3, SD = 191.95) and Stro-4+/ECM-hydrogel (1127.95 mm3, SD = 166.44) groups.
Stro-4+ oBMSCs demonstrated a potential to aid bone repair in vitro and in a small in vivo bone defect model
using select scaffolds. However, critically, translation to a large related preclinical model demonstrated the
https://doi.org/10.1016/j.biomaterials.2020.119998
Received 16 September 2019; Received in revised form 20 March 2020; Accepted 20 March 2020
∗ Corresponding author. Bone & Joint Research Group, Centre for Human Development, Stem Cells and Regeneration, Human Development & Health, Institute of
Developmental Sciences, University of Southampton, SO16 6YD, UK.
E-mail address: Richard.Oreffo@soton.ac.uk (R.O.C. Oreffo).
Biomaterials 247 (2020) 119998
Available online 01 April 2020
0142-9612/ © 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/BY/4.0/).
T
complexities of bringing small scale reported stem-cell material therapies to a clinically relevant model and thus
facilitate progression to the clinic.
1. Introduction
Recent advances in tissue engineering strategies in vitro have in-
creased the demand for suitable in vivo models to progress the pre-
clinical translation of candidate treatments [1]. Indeed the use and
requirement for large animal models in translational medicine has been
widely recognised and established over the past 20 years with canine,
caprine, porcine and ovine species all used to varying degrees [2–4].
The use of sheep in bone tissue engineering continues to gain popularity
and remains a cornerstone of orthopaedic pre-clinical research given
their similarities with humans in terms of: i) weight, ii) joint structure,
iii) physiology and, iv) bone structure. The increasing application of
ovine models in research, therefore, increases the translational poten-
tial of the species model [5,6]. At the centre of many of the skeletal
tissue regenerative strategies remains the bone marrow derived skeletal
stem cell. For translational medicine, it is imperative to translate the
often reported stem-cell material successes observed using small in vitro
and in vivo preclinical studies to clinically relevant models at scale and
thus facilitate progression to the clinic. The need to address basic
questions regarding the safety and efficacy of stem-cell therapies to
recapitulate bone formation and repair at scale, requires, ultimately,
the use of an in vivo model offering physiological and biomechanical
homology to humans [5]. This need has increasingly been met by the
use of ovine orthopaedic models in bone tissue engineering research.
Plastic adherent ovine mesenchymal stem/stromal cells (oBMSCs)
isolated from bone marrow [7,8] peripheral blood [9] and adipose
tissue [10] appear fibroblastoid in culture, show similar CFU-F colony
forming capacity and respond with differentiation in vitro and in vivo as
the human comparator and have now been used successfully as a cell
source in research utilising ovine orthopaedic models [11]. Interest-
ingly, work to date has confirmed the expression of traditional human
(mesenchymal stem/stromal cells) MSC markers on oBMSC populations
including CD29, CD44, CD146 and CD166 [12,13]. However, the ma-
jority of antibodies used are not species-specific and rely on species
cross-reactivity for epitope identification. Therefore, confirmation of
the absence or presence of antigens must be tempered by the knowledge
of the expected specificity of any antibodies used. The accepted criteria
for human MSC definition include the expression of CD73, CD90 and
CD105 [14,15] as markers of cell potency. In contrast, in the sheep,
confirmation of CD90, CD73, CD105 and other common human MSC
marker expression has not been repeatedly demonstrated, however,
confirmation that reported patterns of expression are linked to species
specific phenotypic difference, or merely an antibody specificity-related
false negative remains challenging. Interestingly, the absence of the
endothelial marker CD31 and haematopoietic marker CD45 appears
shared across species. As the literature relating to the in vitro and in vivo
nature of oBMSCs accumulates, it is becoming ever clearer that oBMSCs
behave similarly, both in vitro and in vivo, to their human correlates.
Ovine BMSCs respond to osteogenic, chondrogenic and adipogenic
differentiation cues, expressing the corresponding phenotype as as-
sessed with both histological and molecular techniques [16].
Comparable to species-specific antibody availability, oBMSCs have
been successfully isolated, culture expanded, differentiated and re-im-
planted as both an allogenic and autogenic cell source in various ap-
plications including cardiac, maxillo-facial and bone repair research
[17–19]. The use of immunocompetent large animal models in trans-
lational research requires the identification and characterisation of a
species-specific enriched SSC population. Although candidate markers
for human MSC/SSC enrichment have been detailed in the literature;
including CD146, CD106, CD271, MSCA-1, CD56 and Stro-1 [20–22];
therapeutic targets for use in ovine pre-clinical models remain under-
developed. The conventional anti-human Stro-1 antibody has been
shown to bind to ovine bone marrow mononuclear cells (oBMMNCs) at
a low affinity, selecting for a population 1% of the total stromal fraction
[12]. This low population frequency is unattractive when selecting
candidate markers for prospective cell enrichment and, to this end,
Gronthos and colleagues have developed the monoclonal antibody Stro-
4 as a candidate for skeletal stem cell enrichment of oBMMNCs [12].
Stro-4 designates a monoclonal antibody shown to bind specifically to
human and ovine Heat Shock Protein-90. Stro-4 was produced fol-
lowing modification and adaption of the Stro-1 hybridoma technique,
substituting the CD34 selected inoculation with a CD106 (Vascular Cell
Adhesion Molecule, VCAM) BMMNC sub-population. It was later shown
that the Stro-4 supernatant selected for a phenotypically separate cell
subset to the parent CD106 positive cells used for hybridoma inocula-
tion. The Stro-4 monoclonal IgG antibody has been shown to cross-react
with a discrete population of human and oBMSCs. Furthermore, cells
FACS selected for Stro-4 expression, were shown to enrich for CFU-F
capacity some 8–16 fold, respectively [12]. Comparisons between
human and ovine Stro-4+ populations demonstrated accumulation of
Alizarin-Red positive deposits, alcian blue proteoglycan matrix and
intracellular lipid expression following exposure to osteo/chondro and
adipogenic media, in vitro and in vivo. Thus, the similarities between
ovine and human MSCs appear robust, and, furthermore, Stro-4+ ovine
BMSCs behave comparably in vitro to the human equivalent. The ability
to generate cartilage, bone, stroma and marrow adipocytes is a char-
acteristic of the skeletal stem cell, denoting an ability to form skeletal
lineages, referring to the self-renewing stem cell of the bone marrow
stroma responsible for the innate regenerative capacity of bone [23,24].
Thus, enriched ovine BMSCs can be regarded as a translationally re-
levant target for cell enrichment in ovine orthopaedic models.
In keeping with these aims of developing multifaceted solutions to
augment bone formation and application in bone tissue engineering, we
examined the functional characteristics of ovine bone marrow derived
skeletal stem cells from cellular and molecular laboratory investigations
through to evaluation in a large scale in vivo bone defect model. We
have examined the characteristics of an oBMSC population subset se-
lected using the Stro-4 antibody and, critically, the efficacy of the ovine
enriched BMSCs for skeletal repair assessed using a bone extracellular
matrix hydrogel and melt electro-written medical-grade poly-
caprolactone (mPCL) tubular scaffolds. Regeneration was examined in a
highly vascularised small in vivo model as well as in a large clinically
relevant segmental ovine bone defect model.
2. Material & methods
2.1. Materials
The Stro-4 antibody was generated as previously detailed by
Zannettino and colleagues, University of Adelaide [12]. Foetal calf
serum was obtained from Life technologies, Scotland UK. Remaining
cell culture reagents were purchased from Sigma-Aldrich, UK unless
stated. Fertilised eggs were purchased from Medeggs, Norfolk, UK.
2.1.1. Stro-4 magnetic activated cell separation of oBMSCs
Ovine Stro-4 cell isolation from whole bone marrow was adapted
from protocols to isolate human Stro-1 from human bone marrow as-
pirates [25,26]. Briefly, 5–8 mL of sheep iliac crest bone marrow as-
pirate was obtained aseptically immediately post-mortem. Marrow
samples were collected in basal tissue culture medium (alpha-MEM,
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10% foetal calf serum, penicillin/streptomycin) washed and filtered
into single cell preparations before undergoing density dependant
centrifugation, erythrocyte depletion and mononuclear cell fraction
enrichment. The enriched mononuclear fraction was prepared for an-
tibody labelling by incubation in a protein blocking solution containing
2% human and bovine serum. Cells were then centrifuged and re-sus-
pended, washed with 1x PBS and approximately 1 × 108 cells were
incubated in neat Stro-4 supernatant on ice for 30 min. Cells were
washed in 1x PBS, and the Stro-4 labelled oBMSCs were incubated with
goat anti-mouse IgG MicroBeads (Miltenyi Biotech, UK) at 20 μL per
1 × 107 cells (approximately 200 μL of beads) for 15 min on ice. The
labelled cells were then re-suspended in MACS buffer, passed through a
MACS column magnets (QuadroMACS and MACS columns, Miltenyi
Biotech), and the positive fraction from each sample was collected,
counted and seeded onto standard tissue culture plastic cell culture
flask at 1× 104 cells per cm2. Cells were cultured in basal tissue culture
medium at 37 °C, 5% CO2 in balanced air.
2.2. Flow cytometric analysis
Cultured ovine MSCs were incubated in blocking buffer (Hanks
Buffered Saline Solution + 20 mM Hepes, 1% normal human AB serum,
1% bovine serum albumin (BSA: Cohn fraction V, Sigma Aldrich Pty
Ltd, NSW, Australia), and 5% FCS for 20 min on ice. For each analysis,
1 × 105 cells were resuspended in 100 μL of 10 μg/mL primary anti-
body, anti-CD14, -CD31, -CD34, -CD45 (BIO-RAD Hercules, CA), anti-
STRO-4, -CD29, -CD44 [12], anti-CD90, or –CD166 (BD Biosciences San
Jose, CA) for 45 min on ice. The isotype-matched, non-binding control
antibodies, antibodies, IgG (BIO-RAD) was used as culture supernatant
under identical conditions. The cells were then washed in HBSS with
5% FCS and incubated with a goat anti-mouse IgG (γ-chain specific)
phycoerythrin (PE) (1/50; Southern Biotechnology Associates, Bir-
mingham AL) for 30 min on ice. Prior to analysis, cells were washed
twice in HBSS with 5% FCS and resuspended in PBS/1% paraf-
ormaldehyde. Flow cytometric analysis was performed using an Epics-
XL/MCL flow cytometer (Beckman Coulter, Hialeah, FL). The analysis
was performed using the FlowExpress software.
2.3. Proliferation and Colony Forming Unit capacity of Stro-4+ vs
unselected oBMSCs
2.3.1. Population doubling time
Population doubling time was measured by plating 1 × 103 cells/
cm2 in T75 flasks, growing cells in basal media until approximately
60% confluence. Cells were washed in 1x PBS, enzymatically digested
(1x Trypsin/EDTA solution), washed and centrifuged before resuspen-
sion in 2 mL of culture media. The total number of cells was recorded
before cells were re-plated at 1 × 103 cells/cm2. This process was re-
peated from passages 0–5 using a total of 5 animals. Population dou-
bling time, the time taken in hours for the total number of cultured cells
to double in number, was calculated as follows:
Population Doubling Time = Time (in Hours) Log2 [Log (Final Cell
Number) – Log (Seeded Cell Number)]
2.3.2. Colony Forming Unit capacity (CFU–F)
Assessment of clonogenic capacity was carried out using the Colony
Forming Unit-Fibroblast (CFU–F) assay [27]. Cultured Stro-4+ and
unselected cells from early passage 0 to late passage 5 (1 × 101/cm2),
were plated into T-25 flasks and cultured in basal culture medium. 14
day cell cultures were washed in 1x PBS, fixed in 85% ethanol before
being air-dried. The fixed cultures were stained for alkaline phospha-
tase (ALP) by incubation with naphthol AS-MX phosphate (40 μL/mL)
and Fast Violet B salt (2.5 μg/mL) in distilled H2O for 45 min at 37 °C
under 5% CO2 in a humidified atmosphere in the dark. ALP+ve colonies
(colonies exhibiting ≥50% ALP+ve stain across their diameter) were
labelled and counterstained for 5 min with haematoxylin. Colonies
comprising of> 32 cells were analysed. Colonies were washed in 1x
PBS air dried, imaged and counted via light microscopy.
2.4. Multi-lineage differentiation of oBMSCs
2.4.1. 2-Dimensional in vitro culture assay
The potential for Stro-4+ oBMSCs to differentiate into osteogenic,
chondrogenic and adipogenic lineages was carried out as previously
stated for human skeletal stem cells [28] with adaptations outlined
briefly due to the accelerated growth characteristics observed for ovine
cells. Differentiation of the cells into the three lineages was assessed at
day 21 using both histological and molecular techniques of cells grown
in monolayer culture.
Each donor sample was plated in a 6 well plate at 2 × 104 cells per
well, two wells per condition, both Stro-4+ and unselected cells. Two
wells per condition for both cell types were cultured in basal media as
experimental controls. Cells were first cultured in basal media; 10%
FCS, 1% P/S, α-MEM until 20–30% confluent then switched to 1.5 mL
per well lineage-specific media (Osteogenic: α-MEM with 10% FCS,
100 μM Ascorbate-2-phosphate, 10 nM Dexamethasone, 25 nM 1α, 25-
dihydroxy Vitamin D3, 10 mM β-glycerophosphate. Chondrogenic: α-
MEM with 100 μM Ascorbate-2-phosphate, 10 nM Dexamethasone, 1%
insulin, transferrin, selenium (ITS) medium supplement, and 10 ng/mL
TGF- β3. Adipogenic: α-MEM with 3 g/l D + Glucose, 10% FCS, 3 μg/
mL insulin, transferrin, selenium (ITS), 100 nM Dexamethasone,
0.5 mM IBMX, and 1 μM Rosiglitazone). Culture media was changed
twice a week over 21 days. Cells were either fixed appropriately for
histological staining or lysed in preparation for molecular analysis.
2.4.2. Chondrogenic, osteogenic and adipogenic staining of unselected and
STRO-4+ enriched oBMSCs
The monolayer cell cultures were washed twice with PBS and then
fixed with 4% paraformaldehyde at room temperature for 15 min.
Another series of washes were done with Mili-Q H2O (each wash at
5 min). For chondrogenesis; cells were stained with 0.5% Alcian blue
8GX for proteoglycan-rich cartilage matrix for 15 min and washed with
1x PBS. For osteogenesis; 0.2 mL of 40 mM alizarin red solution was
added and incubated for 1 h on a rotating plate. The samples were then
washed 5 times with dH2O. Alizarin red was used to stain calcium de-
posits with orange/red colour. For adipogenesis, Oil Red O staining was
used. Cell cultures were fixed in Baker's formal calcium, washed in 60%
isopropanol, and stained with double-filtered Oil Red O solution for
15 min to show for cytoplasmic lipid accumulation. All stained cells
were imaged under using a Carl Zeiss Axiovert 200 microscope. Carl
Zeiss Axiovision 3.1 software package was used to capture the stained
cells.
2.4.3. Stro-4+ vs unselected in vitro characterisation
Unselected and Stro-4+ cells were culture expanded in basal tissue
culture medium at 37 °C, 5% CO2 in balanced air. After the first pas-
sage, cells were seeded into 6-well plates at 2 × 104 cells per well, three
well per condition (and with 3 replicates, 9 wells per condition), and
grown in basal media. As previously stated cell culture media was
switched to chondrogenic or osteogenic as appropriate and culture
extended to 14 days with media changed every 72 h. Cells were fixed
and stained with Alcian Blue (chondrogenic differentiation) and
Alizarin Red (osteogenic differentiation) as previously stated and
quantified for staining intensity following an automated pipeline using
an open source image analysis software (CellProfilerTM, The Broad
Institute, USA). Three x4 magnification images were captured across
the equator of the well. Images were uploaded into CellProfiler and
analysed using the pipeline: convert to greyscale > Area of interest
colour red > Quantify (Supplementary fig.1) Overall intensity was
normalised to the cell count per image field by performing an object
count on DAPI stained images. Staining intensity of cells cultured in
basal, chondrogenic or osteogenic media was expressed as intensity
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units per cell.
2.4.4. 3-Dimensional chondrogenic in vitro culture assay
Ovine Stro-4+ and unselected cells were grown in micromass cul-
tures. In brief, passage 1 cells were resuspended in basal media at a
concentration of 1 × 104/μL. Micromass cultures were formed by de-
positing 30 μL of cell suspension into a well of a 6-well plate, droplets
were pipetted carefully on the plate surface. Three micromass cultures
were placed per well then allowed to adhere by incubating for 2 h at
37 °C. Cultures were gently covered with 1.5 mL standard chondrogenic
media and cultured for 21 days.
2.4.5. Molecular analysis
Unselected and Stro-4+ skeletal populations obtained from dif-
ferent sheep (n = 4) were cultured for 21 days in conditioned media for
tri-lineage differentiation, as previously stated. The potential to differ-
entiate into adipocytes, osteoblasts and chondrocytes was assessed
using relative gene expression levels of differentiation markers using
quantitative RT-PCR (Supplementary Table 1). Total RNA (500 ng) was
extracted from cultured samples using an Isolate II RNA Mini kit (Bio-
line), according to the manufacturer's instructions. RNA was im-
mediately reverse-transcribed with TaqMan Reverse Transcription Re-
agents (Applied Biosystems). RNA concentration was evaluated using a
NanoDrop 1000 spectrophotometer (Thermo Scientific, UK). Relative
quantification of gene expression was performed with an ABI Prism
7500 detection system (Applied Biosystems). Primer Express 3.0 soft-
ware (Applied Biosystems) was used to design all primers in the current
study. The 20-μL reaction mixture was prepared in triplicate, con-
taining 1 μL of complementary DNA, 10 μL of GoTaq qPCR Master Mix
(Promega), and 1 μM of each primer. Thermal cycler conditions in-
cluded an initial activation step at 95 °C for 10 min, followed by a 2-
step PCR program of 95 °C for 15 s and 60 °C for 60 s for 40 cycles. The
2−ΔΔCt method was used for relative quantification of gene expression,
and the data were normalised to β-actin expression (Supplementary
Table 1 – Primer sequences).
2.5. In vivo assessment of Stro-4+ oBMSCs in bone regeneration
2.5.1. Ex-vivo femur defect cultures in the chorio-allantoic membrane
model (CAM)
Chick femurs were harvested from embryonic day 18 chicks by
carefully removing the proximal and distal hind limbs. The femur was
carefully disarticulated distally from the femoro-tibial joint, and
proximally at the femoro-acetabulum. Precaution was taken to ensure
that neither cartilaginous epiphysis were removed from the calcified
diaphysis. Once the femora were isolated, all remaining extra-osteal
tissue was removed. Freshly isolated femora were placed in α-MEM and
kept overnight in a tissue culture incubator (37 °C, 5% CO2 in balanced
air).
All egg CAM procedures were carried out in accordance with the
guidelines and regulations stipulated in the Animals (Scientific
Procedures) Act, UK 1986. The chick embryo CAM model was under
Home Office Project license (PPL 30/2762). On the day of implantation
into the CAM, sequentially; each femur was removed from storage
media and placed onto sterile filter paper to remove excess culture
media, then using a scalpel, the femur was transected mid-shaft. An in
house-built melt eletrowriting device, a technology combining additive
manufacturing and electrospinning system, was used to fabricate the
tubular mPCL scaffolds with medical-grade polycaprolactone (Purasorb
PC 12, Purac Biomaterials, The Netherlands) following a previously
described methodology [29]. Next, sections of sterile melt electro-
written mPCL tubular scaffolds were cut, approximately 5 mm in length
and 2 mm in diameter. Using fine-toothed forceps, the mPCL scaffold
was carefully pulled over the sectioned ends of each femoral half at-
tempting to leave a 2 mm gap or defect between femoral segments
(Supplementary Fig. 2).
Once each femur was secured in place using a 5 mm scaffold seg-
ment, the femur/scaffolds were placed in a sterile dish and held in place
by forceps. Femurs were divided according to experimental groups.
Group I: Femur and mPCL scaffold (n = 6); Group II: Femur/mPCL
scaffold/ECM hydrogel (n = 6); Group III: Femur/mPCL scaffold/ECM
hydrogel and Stro-4+ oBMSCs (n = 6). Bovine bone extracellular
matrix (bECM) hydrogel was prepared using a protocol adapted from
Pietrzak et al., 2011 [30] and further characterised by Sawkins et al.,
2013 [31]. In brief, bovine bone samples underwent sequential mor-
salisation, demineralisation to form a demineralised bone matrix
(bDBM), chloroform/ethanol-based lipid removal and a final decel-
lularisation step to produce a bovine bECM material. bECM was sub-
jected to solubilisation and pepsin digestion to prepare a functional
hydrogel [30,31]. In groups containing the hydrogel, the needle was
inserted into the lumen of the scaffold and femoral defects with care
taken not to damage any construct components nor dislodge either end
of the femur. Once the constructs were completed, they were placed
onto the CAM. CAM eggs with implants were sealed and placed into the
Hatchmaster (Brinsea UK) with rotation turned off and cultured for 8
days.
2.5.2. Ovine tibial segmental defect model
The studies were undertaken following approval from the animal
ethics committee of the Queensland University of Technology (animal
ethics approval no. 16). Sixteen experimental animals (aged male,> 6
years old, merino-cross sheep) were divided amongst two experimental
groups, (Supplementary Table 2).
For the sheep tibial defect model, tubular mPCL scaffolds with a
length of ~6 cm and diameter of ~2 cm were fabricated using melt
electrowriting technology (Supplementary Fig 3). bECM hydrogel and
mPCL scaffold constructs without cells (n = 8) and bECM hydrogel and
mPCL scaffold constructs seeded with Stro-4+ oBMSCs (n = 8)
(Supplementary Fig. 2). Surgical protocols were based on those pub-
lished by Reichert et al,. 2010 [32]. In brief, a linear incision, ap-
proximately 12 cm in length was made on the medial aspect of the
distal pelvic limb, extending proximally from a point 1 cm below the
tibial plateaux and distally to the medial malleolus. A customised dy-
namic compression plate (DCP), 5.2 mm broad, 10 holes, (Synthes™),
was contoured to the morphology of the bone with a plate bending
press (Synthes™) and the fit confirmed against the intact bone. The
distal end of all plates was placed exactly 2.5 cm proximal of the medial
malleolus.
A line marking the centre of the defect was made using a rasp. A
point 1.5 cm proximal and 1.5 cm distal to the centre mark was made
using the oscillating saw. These defined precise osteotomy lines for a
3 cm tibial diaphyseal defect. Screw holes were pre-drilled, 3 proxi-
mally and 2 distally to the osteotomy line. The periosteum was removed
above and below the defect to inhibit the healing response and max-
imise the regenerative challenge. The tibial diaphyseal defect was cre-
ated with limb stability provided by a customised unilateral 5.3 mm
DCP secured with 3.5 mm self-tapping screws.
Melt electro-written scaffolds were applied, sutured in place and
anchored by application of the DCP plate on the abaxial surface of the
defect. In both groups, 8 mL of sterile bovine bECM pre-gel solution was
injected into the defect lumen, localised by mPCL scaffold. Seeded
bECM pre-gel solution were combined with cultured ovine Stro-4+
oBMSCs at a density of 4 × 106/mL of gel material. Seeded and un-
seeded treatments were warmed to room temperature immediately
prior to application and gelation allowed to occur in situ before the
defect wound was sutured closed (Supplementary Fig. 4).
The operated limb was cast in fibreglass tape which was split after
one week and used as a bivalve splint for a further two weeks. The
animals were not immobilised following surgery and were permitted to
weight-bear immediate following recovery from surgery. The full extent
of bone weight-bearing was minimised during the first 3 weeks post-
operation by the leg cast and splint. Animals were routinely examined
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for lameness, inflammation, infection and wound complication. All
animals recovered without complication from surgery. Two animals
were removed from the study after 6 weeks due to plate bending, no
animals were excluded relating to complications of bone fracture. The
remaining fourteen animals continued through to 3 months without
clinical complications. Findings were combined with historical data
from empty and autograft controls.
2.6. Analysis of in vivo models
2.6.1. Micro-computed tomography (μCT)
3D analysis of PFA fixed organotypic cultured chick femurs/hy-
drogels, and chick femur defects/hydrogels with Stro-4+ cells were
performed using a SkyScan 1176 scanning system (Bruker μCT,
Kontich). Samples were scanned at 18 μm resolution and reconstructed
using NRecon software interface (v.1.6.4.6, Bruker μCT, Kontich).
Reconstructed femurs and hydrogels were analysed using CT Analyser
(v.1.13.2.1+, Bruker μCT, Kontich) and images generated using CT Vox
3.0.
For the ovine tibial segmental defect model, fixed bone samples
were scanned at 18 μm resolution using a Scanco μCT 40 micro-CT, files
were converted to .ISQ format and analysed in combination with con-
trol data at the University of Southampton using ctAn software (Bruker
μCT, Kontich). The defect region was identified using the drill holes
nearest to the defect boundary as landmarks, with the defect universally
defined 0.5 cm proximal and distal to the respective drill holes.
Thresholding was set uniformly for all analysis, advised on an Otsu
analysis. The defect region was analysed in four segments, proximal,
middle, distal and whole for bone volume (BV mm3). Only values for
the whole defect region were included due to the absence of new bone
formation demonstrated in test groups. Bone volume was calculated
using Bruker Skyscan® ctAn software.
2.6.2. Chick femur/CAM histology
Following μCT analysis, chick femur defect samples were dehy-
drated through a series of ethanol washes (50%, 90% and 100% in
dH2O) and incubated in Histo-Clear (National Diagnostics). Following
incubation in paraffin wax for 1 h at 60 °C, samples were embedded in
wax blocks using an automated Shandon Citadel 2000. Consecutive
7 μm thick sections were cut throughout the depth of the central hy-
drogel insert. Mounted sections were rehydrated through Histo-Clear,
graded ethanol's and dH2O before staining for the nuclear counter-stain
Weigert's haematoxylin, followed by staining with 0.5% Alcian blue
8GX for proteoglycan-rich cartilage matrix and 1% Sirius red F3B for
collagenous matrix. Additionally, separate slide sections were stained
for Goldner's Trichrome to detect bone and osteoid according to stan-
dard protocols. Sections were then dehydrated and mounted with DPX
before imaging with an Olympus BX-51/22 DotSlide digital virtual
microscope using OlyVIA 2.1 software (Olympus Soft Imaging
Solutions, GmBH).
2.6.3. Sheep tibial defect histology
Following μCT analyses, tibial bone specimens were frozen and
trimmed to 6 cm length and fixed in freshly made 4% paraformalde-
hyde at 4 °C for a minimum of one week, with fixative replaced every
72 h. For histological analysis, the mid-defect regions were sectioned in
the transverse and sagittal plane. Sections were split between resin and
paraffin embedding. Paraffin-embedded sections were used for hae-
matoxylin and eosin (H&E) staining. Samples for paraffin embedding
were first decalcified in 15% EDTA for 6–8 weeks at 4 °C with regular
Fig. 1. Fluorescence microscopy demonstrating Stro-4 expression in oBMSCs (A–C). Stro-4 (green), nuclear counter stained blue (DAPI). Cells in suspension
immediately post MACS isolation of fresh ovine bone marrow mononuclear cells (A). Stro-4 expression of adherent passage 0 cells (B). Loss of Stro-4 expression by the
end of passage 3 (C). Scale bar = 50 μm. Immunophenotype of cultured sheep MSC (D). Single cell suspensions of passage 2 ovine MSC were assessed for their
expression of cell surface levels of MSC associated markers (STRO-4, CD29, CD44, CD90, CD166), haematopoietic markers (CD14, CD34, CD45) and endothelial
marker (CD31) by flow cytometric analysis. The horizontal line was set to the reactivity levels of< 1.0% mean fluorescence obtained with the isotype-matched
control antibody (black line) treated under the same conditions. The histogram represents 2 × 104 events (D). Population Doubling Time (PDT, in hours) of
oBMSCs cultured in vitro (E). Comparative growth rate of Stro-4 (■) and Unselected oBMSCs (●). Error bars = mean ± standard deviation, N = 5 for all time
points and both cell groups. **p < 0.01; ***p < 0.001. Stro-4 and Unselected oBMSCs Colony Forming Unit capacity with passage (F). Stro-4 (■) and
Unselected oBMSCs (●) displayed similar colony–forming capacity from early to late passage. P0 cells demonstrated poor colony-forming capacity in comparison to
that seen at P1 and sustained until P3, slowly tapering off at late passage (P5). Error bars = mean ± standard deviation, N = 5, *p < 0.05. (For interpretation of
the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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EDTA changes. Decalcified samples were dehydrated by sequential
rising percentages of ethanol using an automated tissue processor
(Excelsior ES, Thermo Scientific, Franklin, MA, USA), and embedded in
paraffin wax. Samples were sectioned (5 μm) using a microtome (Leica
RM 2265). The slides were deparaffinised with xylene and rehydrated
prior to H&E staining (Sigma Aldrich). Samples were mounted with
Eukitt (Fluka Biochemica, Milwaukee, WI, USA).
Samples which were resin embedded were fixed in 4% paraf-
ormaldehyde, and serially dehydrated in ethanol from 70% to 100%
graded ethanol for approximately one week in each solution. The
samples were then degreased in xylenes for 8 h.
Following degreasing with xylene, samples were infiltrated and
embedded in the low-temperature embedding system Technovit 9100
New® (Heraeus Kulzer GmbH, Germany) according to Wilbold et al.,
2010 [33]. After polymerisation, the resin blocks were mounted and
sectioned longitudinally at 200 μm using an EXAKT 310 Diamond Band
Saw and subsequently ground at 60 and 70 μm using an EXAKT 400CS
micro grinder (EXAKT Apparatebau GmbH & Co. KG, Norderstedt,
Germany) according to the technique described by Donrath., 1995.
[34]. Histological staining was performed using Goldner's trichrome
staining according to previously published methods [35].
3. Statistical analysis
Statistical analysis of comparisons in cellular staining intensity were
compared by ANOVA with multiple comparisons between groups as-
sessed by Tukey's post hoc multiple comparison test using GraphPad
Prism 6 software version 6.0. Statistical analysis of gene expression was
performed by ANOVA, with LSD non-parametric post hoc testing for
intergroup comparison using SPSS software, expression was normalised
relative to unselected population in basal media. Graphs were gener-
ated using GraphPad Prism. For the Sheep study, statistical analysis was
performed using GraphPad Prism 6 software version 6.0 with graphs
produced in the same software. A one-way analysis of variance ANOVA
was used with Tukey's post-hoc test comparing the means of each group
with one another, and Dunnett's post hoc comparing each group to
blank controls. Significance at p < 0.05 was considered significant.
Only autograft demonstrated significant bone growth,
****p < 0.0001.
Fig. 2. Tri-lineage differentiation of passage 2 (A) & passage 5 (B) Unselected and Stro-4 enriched ovine BMSCs and quantification of chondrogenic (Alcian
Blue) and osteogenic (Alizarin Red) staining in passage 2 (C & D) and passage 5 (E & F) Unselected (Uns) and Stro-4 populations. An enhanced osteogenic
response is seen in the Stro-4 population over unselected, Alizarin red stain (A). Chondrogenic response is comparable between Stro-4 and unselected cell groups with
inherent chondrogenic activity noted in the Stro-4 population under basal conditions, Alcian blue stain (A). Adipogenic response in both groups was present but
unconvincing, assessed by Oil Red O staining (A). Passage 5 cells response to osteogenic media was present in both cell groups although diminished compared to
passage 2, Alizarin red (B). The chondrogenic response in unselected cells had diminished at passage 5 but was conserved in the stro-4 enriched population, Alcian
blue (B). Adipogenic differentiation is absent in both populations. N = 4, both groups for each condition. Scale bar = 200 μm P2 Stro-4 enriched oBMSCs showed
increased alcian blue staining intensity compared to Unselected oBMSCs Stro-4 enriched cells (C). Both P2 populations demonstrated a positive phenotypic change
under osteogenic conditions but did not show a significant difference between unselected and enriched populations (D). In contrast to chondrogenic differentiation,
no innate osteogenic response was noted under basal culture conditions (d). Under both basal and chondrogenic conditions, P5 Stro-4 enriched oBMSCs responded
positively showing significant increases in staining intensity compared to Unselected cells (E,F). The response pattern between groups appears similar to that seen at
passage 2 (E,F). Cellular response to osteogenic media diminished in late passage (F). Although an osteogenic response was present there was no significant difference
in osteogenic response between conditioned and basal media (F). N = 4, error bar = mean ± SD. . *p < 0.05, **p < 0.005, ***p < 0.001. (For interpretation of
the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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4. Results
4.1. The expression of Stro-4 in OBMSCs
The presence of Stro-4 antigen expression was confirmed by fluor-
escent immunolabeling of freshly sorted cells with temporal expression
of Stro-4 monitored by immunofluorescence over successive passages
until a signal was no longer detectable (Fig. 1A–C). The expression of
Stro-4 declined rapidly after initial passage and was uniformly absent in
passage 3 cells. The absence of Stro-4 at passage 3 subsequently de-
termined the definition of early and late passage cells (presence and
absence of Stro-4 antigen). Furthermore, increased subject samples,
tested at P0, showed a significant increase in CFU-F population num-
bers in the Stro-4+ enriched populations compared to the unselected
cells (Supplementary Fig. 5).
4.2. In vitro characterisation of Stro-4+ skeletal cell populations
Single cell suspensions of passage 2 ovine skeletal populations were
assessed for their expression of cell surface levels of: i) MSC associated
markers (STRO-4, CD29, CD44, CD90, CD166), ii) haematopoietic
markers (CD14, CD34, CD45) and iii) endothelial marker (CD31) by
flow cytometric analysis. Ovine BMSCs expressed high levels of MSCs
associated markers – specifically CD29 (99.4%), CD44 (99.59%), CD90
(99.45%), CD166 (99.71%) and Stro-4 (99.73%) (Fig. 1D). Negligible
expression of the endothelial associated adhesion marker CD31 (1.17%)
and the haematopoietic markers CD45 (1.10%) and CD34 (0.06%) was
observed.
4.3. In vitro growth characteristics -population doubling time (PDT)
Skeletal stem cell primary culture is characterised by a variable
period of adhesion enabling cell recovery, expression of adhesion mo-
lecules, settling and adherence to tissue culture plastic. Initial popula-
tion doubling times (PDT) were observed to be 100 cells per cm2 at
initial seeding. The population doubling time remained at between 20
and 30 h for passages 1 and 2 with growth rate declining from passage 3
with a PDT of 24–64 h. The growth profile for selected and unselected
cells, over passages 4 and 5, reduced to give a PDT range between 38
and 110 h at P5, (Fig. 1E). Variation between samples and across both
groups was noted to increase with passage. The observed variations in
growth profile correlated with changes in morphology and CFU-F ca-
pacity over time and passage (Fig. 1E).
4.4. Colony Forming Unit-Fibroblast (CFU–F) assay
CFU-F potential was assayed by contact independent tissue culture
plastic adherence and proliferation with selected and unselected po-
pulations indistinguishable, statistically, at each measured CFU-F time
point. CFU-F numbers were observed to be lowest for all passages at
39 ± 9 colonies/750 cells. Primary passage cell growth was sig-
nificantly lower than P1 and P2 in unselected and Stro-4+ populations,
while, CFU-F numbers in selected populations, at P3, was significantly
higher than unselected primary cultures. CFU-F numbers were noted to
be consistent at 102 ± 8 colonies/750 cells between passages 1–4 for
both cells groups over all time points. Colony formation was noted to
decline at passage 5 in selected and unselected populations but did not
reach statistical significance (Fig. 1F).
5. Tri-lineage differentiation of ovine Unselected and Stro-4+
oBMSCs at early and late stage passage culture
Early and late passage Stro-4+ selected and unselected oBMSCs
were observed to grow rapidly under basal culture conditions. Early
passage Stro-4 enriched populations displayed lineage-specific differ-
entiation under basal and chondrogenic conditions compared to un-
selected cells (Fig. 2A,C). A similar response was observed in late pas-
sage 5 cells (Fig. 2B,E). Under osteogenic and adipogenic culture
conditions differentiation was observed in Stro-4+ and unselected
populations at early passage (Fig. 2A,D) compared to basal cultured
cells. Minimal osteogenic and adipogenic differentiation was observed
in late passage (P5) cells (Fig. 2B,F).
Fig. 3. Relative expression of differentiation markers of unselected and selected (Stro-4+) cells in monolayer and micromass cultures for 21 days.
Expression of osteogenic (A–B), adipogenic (C) and chondrogenic (D–F) markers was analysed by quantitative reverse transcription-polymerase chain reaction. Data
are shown as median ± SD of triplicate determinations per sample (n = 4). Statistical differences were calculated by Mann-Whitney U test (*P < 0.05).
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6. Molecular analysis of osteogenic-, adipogenic- and
chondrogenic gene expression in un-selected and selected Stro-4+
oBMSCs
Expression of the osteogenic markers COL1A1 and osteocalcin
(OCN) was observed to be variable between media conditions and cell
populations. Stro-4+ cell cultures showed a 1.64-fold increase under
osteogenic conditions, while no increase in COL1A1 gene expression
was observed for unselected cells (Fig. 3A). Interestingly, COL1A1 gene
expression was upregulated 4.38-fold increase in unselected and 5.36-
fold increase in Stro-4+ cells across both cell populations under
chondrogenic culture conditions (Fig. 3A). No significant differences
were found in OCN expression in both cell populations cultured in os-
teogenic media conditions (Fig. 3B). However, under chondrogenic
conditions, potential upregulation of OCN was observed with un-
selected cells displaying a 6.59-fold increase and Stro-4+ cell cultures
3.04-fold increase compared to basal cultured cells (Fig. 3B).
PPARG mRNA expression levels were modestly increased, under
basal conditions Stro-4+ cells showed a 1.27-fold compared with un-
selected cells. PPARG expression was significantly increased under
adipogenic conditions, showing in unselected cells 3.34-fold increase
and, a 4.07-fold increase in Stro-4 selected populations, although these
did not reach statistical significance (Fig. 3C).
The chondrogenic markers COL2A1, aggrecan (ACAN) and SOX9
showed significant gene expression increase under chondrogenic cul-
ture conditions in both unselected and Stro-4+ cells (Fig. 3D–F). Un-
selected cells showed a 216-fold increase in COL2A1 mRNA levels
whilst Stro-4+ cells demonstrated a 1760-fold increase in chondro-
genic conditions compared to basal conditions in monolayer culture.
Stro-4+ populations also showed a 6.12-fold increase in COL2A1 gene
expression when cultured in basal conditions compared to unselected
cells (Fig. 3D). A similar response with ACAN gene expression was
observed, unselected cells showed a 630.34-fold increase compared to a
1831.34-fold increase in the Stro-4+ cells under chondrogenic condi-
tions. Moreover, ACAN gene expression showed a 20.44-fold increase in
Stro-4+ cells under basal conditions compared to unselected cells
(Fig. 3E). SOX9 expression levels were upregulated in chondrogenic
culture conditions, showing a 5.98-fold increase in unselected cells
compared to 6.34-fold increase in Stro-4 populations (Fig. 3F).
3D micromass cultures using unselected and selected populations
showed a significant increase compared to the basal cultured groups.
COL2A1 relative expression showed a 1681.9-fold increase and a 415.7-
fold increase in unselected and Stro-4+ populations, respectively
(Fig. 3D). For ACAN relative expression levels, Stro-4+ cells showed a
118.57-fold increase compared to a 174.34-fold increase in unselected
cells (Fig. 3E). Similar results were found for SOX9 mRNA expression
levels, a 56.89-fold increase and a 22.65-fold increase in unselected and
Stro-4+ population, respectively (Fig. 3F).
Micromass culture in chondrogenic media showed a significant
upregulation compared to basal conditions in this 3-D culture model.
COL2A1 showed a 9297.29-fold increase in unselected cells and a
4904.08-fold increase in Stro-4+ cells (Fig. 3D); ACAN showed a
3935.52-fold increase and a 2018.06–fold increase expression respec-
tively (Fig. 3E). On the other hand, no significant increase in SOX9
expression was observed (Fig. 3F).
7. Evaluation of bone formation using Stro-4+ oBMSCs in the
bone defect/CAM model
Bone formation was assessed using embryonic chick femur (E18)
defect implanted with oBMSCs in a unique carrier system
(mPCL + bECM) consisting of a proprietary mPCL microfiber scaffold
and bECM hydrogel. Excellent integration was observed of the bone
defect/microfiber scaffold/hydrogel/Stro-4+ (group 3)construct with
the vascular rich CAM (Fig. 4A–C). In all three groups (control; blank
mPCL scaffold), carrier (ECM) and carrier seeded with oBMSCs showed
evidence of good integration with the CAM membrane (Fig. 4A–C) with
marked soft tissue and blood vessel invasion into the implant. μCT
evaluation in the control defect showed a clear boundary demarcation
between femur segment ends with negligible signs of new bone growth
(Fig. 4Ai & Aii). In the carrier group (mPCL scaffold and ECM hydrogel,
unseeded) bone segments at either end of the defect could be deli-
neated, and a modest degree of “softening” to the defect edges was
evident, linked to early new bone tissue formation (Fig. 4Bi & Bii). In
the Stro-4+ oBMSCs-mPCL scaffold (group 3), there was clear blood
vessel and soft tissue ingrowth visible macroscopically. Blood vessel
ingrowth was ubiquitous with numerous smaller vessels visible in
comparison to the control and carrier alone groups. μCT analysis de-
monstrated the boundary defect region to be completely filled and
bridged with new bone with a comprehensive volume of new bone
Fig. 4. CAM cultured chick femur defects with Stro-4+ mPCL ECM. Femur with mPCL mesh only (blank scaffold) (A); Femur with mPCL and ECM (B); Femur
with mPCL scaffold, ECM hydrogel seeded with Stro-4+ oBMSC (C); N = 3, Scale bar = 2 mm. Micro-Computed Tomography images of day 18 CAM femurs. Stro-
4+ mPCL scaffold ECM Hydrogel constructs. Unseeded scaffold alone (Ai & Aii); Unseeded scaffold and blank ECM (Bi & Bii); mPCL scaffold and Stro-4+ Seeded
ECM (Ci & Cii). No new bone growth was noted in blank scaffold. Areas of low opacity noted in the blank and blank ECM controls. New bone formation and bony
bridging was observed in the Stro-4+ seeded ECM/mPCL scaffold group. N = 3, scale bar = 3 mm.
C. Black, et al. Biomaterials 247 (2020) 119998
8
formation in the structure of longitudinal bone columns and nodules
under saggittal view. (Fig. 4Ci & Cii).
Histological sections stained for alcian blue/Sirius red demonstrated
a clear demarcated perpendicular transection of the defect femur after
the culture period in the femur defect with just the mPCL-scaffold
alone, where the cut ends displayed no new bone outgrowth nor in-
dications of cellular hypertrophy (Fig. 5A and B dashed black box). A
mild periosteal reaction was observed as non-specific cellular infiltra-
tion into the periosteal region continuous with the peripheral cortical
bone, indicating an obvious non-healing blank defect (Fig. 5A and B).
With the addition of the ECM hydrogel into the mPCL scaffold en-
compassing the femur defect, the boundaries of the defect ends of the
bone remained visible (Fig. 5C and D).
However, with the addition of Stro-4+ oBMSCs to the ECM partial
bridging was observed originating from the central trabecular bone
region, with new growth characterised by red-staining bone spicules
containing entrapped hyperplastic cells in an enlarged peri-cellular
space. The cells within the new bone spicules displayed negligible al-
cian blue staining. However, a thickened hyper-cellular connective
tissue membrane appears to have invaded the defects space, with a
degree of bony bridging and partial repair (Fig. 5E and F).
Within the femur defect site containing the Stro-4+ cells en-
capsulated in the acellular mPCL scaffold-hydrogel the defect boundary
could be identified by columns of bone, orientated parallel to the dia-
physeal axis (Fig. 6A and B). Trabecular-like new bone growth, bridging
the bone defect were observed by extensive Sirius red staining (Fig. 6C
and D). Areas of new bone were observed consistent with periosteum-
like material surrounding the femoral diaphysis. (Fig. 6F).
Interestingly, the trabecular-like bone appeared to have developed
in a perpendicular orientation to the bone defect ends (Fig. 6E and F).
Hypertrophic cell clusters within the newly formed bone were rich in
proteoglycans (Alcian blue staining) (Fig. 6B and C) furthermore, seams
of osteoid matrix were observed peripheral and centrally within the
bridge defect site (Fig. 6E–H).
8. Evaluation of oBMSCs modulation of bone formation using
bECM and mPCL scaffolds in an ovine tibial segmental defect
8.1. μCT
Micro-CT analysis was performed on data from the current experi-
ment and combined with historical control data from Ref. [32] 3-D
renders were compiled for qualitative comparison and bone volume
analysis performed for quantitative analysis. The growth profile within
blank samples was characterised by a low total amount of new bone and
the absence of bone bridging at the three-month time point. In all cases,
a degree of ossification was seen along the fixation plate. The total
amount of bone in the area was variable but clearly distinguished from
bone growth originating from the defect boundaries indicating “new
bone”. Spicules of bone were observed orientated along the line of the
neurovascular bundle, unlike plate-related bone growth, although this
was not always present. The degree of new bone originating from the
bone medulla and cortical edges was minimal. New growth from these
areas rarely projected into the defect more than 5 mm from the defect
edges. In some cases, new bone was detected around the periphery of
the defect, interpreted to be related to the mPCL scaffold. In no case was
any new bone present in the centre of the defect in the blank samples
(Fig. 7A–D).
Autograft samples displayed comprehensive bone bridging of the
defect in all cases (Fig. 7D). There was a small variation in the diameter
of the bone bridge, in only one sample was the diameter of new bone
less than half of the intact cortices either side of the defect. Autograft
samples also displayed large amounts of new bone around the plate -
most evident on sample retrieval whereupon the plate was encased in
new bone. The large volumes of new bone were readily distinguishable
on micro-CT from un-operated bone evidenced by; i) a change in cor-
tical pattern internally and ii) a visually distinctive surface pattern
externally.
Unseeded and seeded test samples were, typically, visually indis-
tinguishable from empty control samples. There were indications of
bone growth which did not match that observed in empty controls.
Fig. 5. CAM ECM-mPCL scaffold Alcian blue and Sirius Red histology. A, B) Blank mPCL scaffold only. C, D) mPCL scaffold and unseeded ECM. E, F) mPCL
scaffold with Stro-4+ oBMSCs seeded ECM. A, C, E scale bar = 500 μm. B, D, F scale bar = 100 μm. Defect boundary demarcated by the black dashed box (B, D, F).
(For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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These changes related to prominent bone outgrowth from the medul-
lary canal (unrelated to intact cortices), low-density irregular spiral
patterned bone outgrowth from proximal and distal defect ends, and in
one case, a consolidated high-density bone fragment located centrally
within the defect as highlighted in Fig. 7A–D.
Autograft samples contained significantly more bone,
(4250.63 mm3, SD = 1485.57) than mPCL (blank) (1045.29 mm3,
SD = 219.68) mPCL + ECM (unseeded; group 2) (1152.58 mm3,
SD= 191.95) and mPCL + ECM+ oBMSCss (cStro-4+ve seeded bECM;
group 3) (1127.95 mm3, SD = 166.44) groups, (Fig. 7E). There was no
significant difference in the volume of bone measured in blank, un-
seeded and seeded ECM groups. New bone growth (bone volume) dis-
tribution was analysed according to the region with the defect. The
total defect was sub-divided into proximal, middle and distal portions
to investigate whether a gravitational effect or displacement of hy-
drogel had occurred and if so, whether the effect translated into a
variation in the location of new bone within the defect. In all groups,
the largest proportion of bone was located in the proximal segment. In
seeded and unseeded groups, bone volume in the proximal segment was
significantly larger than in the middle and distal portions. The proximal
region of autograft samples was significantly enhanced in the middle
sections only. A distinct feature of bone distribution in blank, unseeded
and seeded groups was the near complete absence of bone measured in
the middle portions. In the Blank samples, there were no differences
between the three sub-regions (Fig. 7F).
In the mPCL and unseeded ECM samples (Fig. 8A–D), haematoxylin
and eosin staining (Fig. 8D) indicated poorly aligned tissue with
minimal cellular content. Proximal and distal segments demonstrated
highly cellular marrow cavity components and orientated matrix co-
localised with innate bone. Stro-4+ve seeded samples (Fig. 8E–H),
showed a similar morphology to the unseeded sample under H & E
staining (Fig. 8H). The defect material was characterised by a wash of
non-distinct (pink/purple) eosinophilic material and a low level of
nuclear basophilic material. Central areas lacking staining may re-
present regions of dissolved lipids. Overall, the histological analysis
within these samples indicated repair consistent with fibrous non-
union. In the unseeded ECM samples, Goldner's Trichrome (Fig. 8B), the
proximal and distal tibial segments of innate bone stained a vibrant
blue/green. A small amount of open structured osteoid was visible
sprouting from the bony defect edges. The centre of the defect was
devoid of nucleated tissue, and an empty void was seen on the section
after processing. The central void was surrounded by a loose network of
connective tissue staining orange-red. The region of fibrous tissue was
poorly cellularised, with a randomly deposited matrix containing
Fig. 6. Stro-4+ oBMSCs seeded ECM CAM/bone defect histology. Sample overview of Alcian blue Sirius red histology section staining; 3 regions of interest
demarcated by the dashed box (A). Cluster of proteoglycan producing cells (white arrow) associated with periosteum like membrane (B). Area of hypertrophic cells
(white arrow) associated with invading fibrous sheet (*) (C). Fibrous cellular invasion (*) of defect invading cells appear extra-femoral in origin and have begun
collagen and proteoglycan matrix deposition (D). Sample overview of mineralised and osteoid staining (Goldner's trichrome) (E–H); Area of hypertrophic cells
showing central region of osteoid production (E). Highlighted regions of hypertrophic cells showing clear osteoid production (white arrows) (G, H), cells are
associated with invading collagen, osteoid-like dense tissue (Black arrows). Scale bar A&E = 500 μm, B, C, D, F, G, H = 50 μm. (For interpretation of the references
to colour in this figure legend, the reader is referred to the Web version of this article.)
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pockets of adipose like tissue. In the Stro-4 seeded ECM samples,
Goldner's trichrome (Fig. 8F) staining demonstrated the presence of
mineralised bone on the proximal and distal defect boundaries was
observed. The defect substance was characterised by dense bundles of
red/orange staining collagen fibres and cytoplasm. The fibre distribu-
tion was amorphous and disorganised and contained a discrete amount
of adipose like material. The fibre density in the seeded group was
greater than that in the unseeded with a majority of the defect sub-
stance intensely staining, with only small areas lacking evidence of
collagen (Fig. 8B and F).
9. Discussion
In the current study, we have characterised and studied Stro-4+
oBMSCs in comparison to unselected oBMSC populations and examined
their musculoskeletal regenerative potential in vitro and in small and
large in vivo models using bovine derived ECM hydrogels and a bio-
compatible electro-written PCL. Our in vitro studies demonstrated
oBMSC Stro-4 expression declined with subsequent passaging in
monolayer culture with negligible detection at passage 4. This accounts
for the slow initial PDT demonstrated during the post isolation P0
phase, both unselected and Stro-4+ populations followed a similar
cellular proliferation profile. Ovine BMSCs expressed high levels of
MSCs associated markers including CD29, CD44, CD90, CD166 and
Stro-4 with a negligible expression of the endothelial associated adhe-
sion marker CD31 and the haematopoietic markers CD45 and CD34 in
keeping with our previous reports [7,12]. The persistence of Stro-4 in
oBMSCs has not yet been documented but is in keeping with the pattern
noted in human Stro-1 positive BMMNCs [36]. Growth rates, measured
by population doubling time, in unselected and selected cells were
comparable between populations at each passage between P1 and P5
and was comparable to results demonstrated by others in sheep [9,20]
and humans [20,37,38]. The CFU-F capacity of whole, lymphoprep
separated BMMNCs from ovine bone marrow presented with a mor-
phological and colony-forming potential comparable to findings by
Bruder and Gronthos (above) and similar to CFU-F data reported in
human unselected MSCs [38–40]. Stro-4 CFU-F was documented by
Gronthos et al., 2009 [12] on freshly sorted P0 cells, however, CFU-F
formation with continued passage was not recorded. The results in this
study obtained on growth rate and colony-forming capacity of ovine
unselected BMSCs, compared favourably with the literature and showed
a close homology in the performance of BMSCs between humans and
sheep.
A defined component of an MSC is its ability to differentiate into
skeletal elements. In vitro differentiation on 2-D monolayer culture
under defined conditions results in a demonstrable phenotypic change
towards osteogenic, chondrogenic and adipogenic phenotypes. In
monolayer cultures, both unselected and Stro-4+ cells, under
Fig. 7. Images of the highest bone volume from each experimental group. Empty defect (A), unseeded ECM, region of new bone outgrowth originating from the
distal medullary canal (B), Stro-4+ seeded ECM, new bone formation centrally within the defect unrelated to defect periphery or fixation plate (yellow arrow) (C),
autograft (D). White arrows indicate bone growth associated with fixation implant, orientated uniformly on the cranio-medial aspect of the tibia. Bone growth along
the neurovascular bundle was present in many samples across all groups, orange arrow. Scale bar = 1 cm. Ovine segmental defects μCT analysis. A statistically
significant difference in bone volume was observed between autograft (n = 7) and blank (n = 6), unseeded ECM (n = 6) and Stro-4+ seeded ECM (n = 7) (E). There
were no significant differences amongst other groups. Micro CT analysis of bone distribution by distal, middle and proximal tibial defect regions (F). (For inter-
pretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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chondrogenic culture conditions, significantly enhanced COL2A1,
ACAN and SOX9 gene expression showing a high degree of differ-
entiation towards a chondrogenic phenotype. A similar expression
pattern was established in the micromass experiments, although it ap-
peared that micromass culture was less responsive to further stimula-
tion by chondrogenic media. When examining chondrogenic matrix
deposition by alcian blue staining, Stro-4+ cells at early passage sig-
nificantly outperformed unselected cells. Discordantly, upregulation in
gene expression across both cell groups was observed without any clear
improvement in chondrogenic potential between selected or unselected
groups. The current studies indicate a propensity for ovine cells to
differentiate more readily towards a chondrogenic lineage rather than
an osteogenic or adipogenic phenotype. This is in contrast to the pre-
dominance of Stro-1+ve cells from adult human donors to differentiate
along an osteogenic lineage [36]. Human foetal chondrocytes and MSCs
are known to share common MSC markers and are known to express
higher levels of Stro-1 than an adult cell population [41]. The in-
clination of ovine selected, and to a lesser degree, unselected bone
marrow stromal cells towards chondrogenesis may imply that these cell
populations are able to retain an earlier differentiation lineage pheno-
type. Work by Gotherstrom et al., 2005 [42] demonstrated that the
gene expression of human adult and foetal MSCs varied with foetal
MSCs expressing a less lineage-specific phenotype. One explanation for
the difference in differentiation behaviour between human Stro-1 and
ovine Stro-4 may include a more primitive phenotype in ovine Stro-
4 cells or a propensity for chondrogenic differentiation facilitating en-
dochondral ossification. Work comparing foetal and mesenchymal stem
gene expression would be needed prior to drawing more assertive
conclusions.
The significant osteogenic advantage seen in alizarin red staining of
early and late passage Stro-4+ cells over unselected was not reflected
in gene expression analysis. Neither OCN nor COL1A1 expression were
significantly different in basal and osteogenic conditions in either cell
group. Osteogenic gene expression did correlate with a positive differ-
ence in alizarin red staining noted in osteogenic media of early passage
cells. A variable temporal expression of COL1A1 and OCN in human
MSCs in vitro has been previously demonstrated [43] however, in our
studies gene expression was only performed on day 21 cultures of ovine
Stro-4+ selected and unselected cell populations and may not have
captured peak COL1A1 and OCN expression. Surprisingly, upregulation
of the adipogenic marker PPARG was significantly higher in the Stro-
4+ selected population in both basal and adipogenic conditions.
The bone and cartilage forming ability of Stro-4+ oBMSCs were
assessed in a high-throughput orthotopic chick CAM femur assay using
a novel mPCL scaffold ECM hydrogel system. Previously, the in-vivo
bone and cartilage forming capacity of ovine MSCs has been shown on
HA/TCP and Gelfoam models specific to lineage differentiation [7] and
that the incorporation of skeletal populations into ECM hydrogels has
Fig. 8. Histology images of the tibial defect and ECM hydrogel mPCL scaffold groups: Unseeded ECM (A–D); Stro-4+ seeded ECM (E–H). Schematic diagram of
the tibial defect samples, depicting regions of the histological sections selected for analysis in unseeded and Stro-4 seeded ECM samples (A & E); Goldner's trichrome
staining of tibial sections (B & F); Macroscopic images of the tibial sections obtained from either the proximal or distal regions of the tibial defect (C & G);
Haematoxylin and Eosin stained sections of the proximal and distal regions of the tibial defect (D, H). Scale bar 5000 μm.
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been demonstrated to enhance bone and cartilage regeneration in-vivo
[44–46]. We demonstrated using a novel mPCL scaffold ECM hydrogel
system that in the CAM model (with its proliferative vasculature) un-
seeded hydrogels demonstrated a limited degree of osteoinduction
showing a hypertrophic periosteal reaction and partial bone bridging.
Significant new bone formation was observed in the Stro-4+ oBMSCs
seeded scaffold, which was qualitatively superior to ECM hydrogel
alone when assessed for evidence for orthotopic osteochondral ossifi-
cation. In addition, the external texture of new bone was pitted in ap-
pearance, the significance of which is unknown but may relate to blood
vessel invasion or osteoclastic bone remodelling. We found that staining
concurrently for proteoglycan and calcium aggregation indicated the
presence of chondrogenesis centrally, with osteoblast differentiation
and mineralisation peripherally validating a claim for endochondral
ossification. New bone formation appeared orientated along invading
fibrous tissue and vascular structures and clear differentiation between
innate bone and newly formed bone. Invading fibrous structures appear
intimate and consistent with femoral periosteum, which leads to the
presupposition that new bone is highly dependent on the nature of this
invading tissue and its interaction with ECM and Stro-4 elements. Bone
cells release a number of mitogenic growth factors including VEGF, IGF,
EGF and TGFβ-1 and their paracrine effects on periosteum resident
skeletal cells enhance wound healing in vivo [47]. Periosteum derived
MSCs are multipotent and responsive to both osteogenic and chondro-
genic differentiation in-vivo [48], periosteum and bone marrow derived
MSCs have been shown to upregulate type II collagen production in
response to TGF β1 [49]. Furthermore, MSCs are responsive to chon-
drogenic and osteogenic factors and, MSC exposure to chondroblast
conditioned media enhances bone and cartilage formation in-vivo [50].
Paracrine effects may be inferred by the degree of enhanced peri-
osteal hypertrophy and association of new bone directly with none-
bone tissues seen in the seeded compared to the unseeded group. Stro-
4+ oBMSCs displayed a chondrogenic phenotype even under basal
conditions leading to a hypothesis that the priming influence of Stro-4
enhanced the chondrogenic and osteogenic effect on periosteal skeletal
precursors when implanted ex vivo on to the CAM. The extent to which
Stro-4 contribute directly to new tissue formation through proliferation
and differentiation cannot be determined despite in vitro determination
of growth kinetics as no form of tracking was employed in the seeded
population. Furthermore, the response of Stro-4+ cells in comparison
to, for example, Stro-1+ve cells between ovine and human populations
is unknown.
The development of novel tissue engineering therapies requires a
comprehensive in vivo review in animal models to generate clinically
relevant datasets. Orthopaedic research, in particular, requires animal
models of a comparative size, mass, biomechanics and physiology to the
human patient. Where rodent models are easily accessible and less
expensive they have differing bone morphology to humans and are too
small to critically assess biodegradable repair constructs in bone par-
ticularly in combination with fixation or critical-sized fracture repair.
Hence, sheep have emerged as a well-accepted model expanding our
understanding of species bone structure, anatomy, metabolism and
physiology and therefore fulfilling many of the favourable selection
criteria in translational medicine. Understanding of the cellular biology
within any model is an essential component of regenerative medicine,
in particular, the cells which participate in self-renewal and repair.
Although much is known about human MSC populations, debate re-
mains surrounding the origin, phenotype, tissue location and function.
Previous work by Gronthos and others has opened up our under-
standing of ovine MSCs both in vitro and in vivo [7,10,51] but relatively
little is known concerning selected ovine BMSC sub-populations. Thus,
the current studies build on our previous work on ovine bone marrow
derived cell populations using autologous and allogenic cells in cell-
seeded scaffolds and unloaded scaffolds with autologous bone grafts as
a control group [11] with bone formation assessed 12 weeks post-sur-
gery. We observed no significant differences in bone formation between
the autologous and allogenic groups, in those studies, while we ob-
served enhanced bone formation using cells. Critically biomechanical
analysis indicated no significant differences between the cell groups
and the unloaded scaffolds. In addition, using our standardised 3-cm,
critical-sized tibial ovine defect model there was improved reparative
capacity on delayed injection of allogeneic skeletal cell populations to a
defect site [52]. We have also reported the reparative capacity of such a
tissue engineered construct was less than for autograft and/or a BMP-7
loaded scaffolds [53]. We have also published on a study determining
whether osteoblasts (OBs) isolated from the axial skeleton (tOBs) differ
from OBs of the orofacial skeleton (mOBs) given the different embry-
ological origins of the bones and their capacity for bone regeneration in
a CSD in sheep [54]. We found no significant differences following
biomechanical, microCT and histological analysis of the bone re-
generation potential of tOBs and mOBs in our in vitro study, as well as in
the bone regeneration potential of different cell types in vivo. These
studies provided the backdrop to the current studies that have centred
on the analysis of Stro-4 enriched ovine skeletal populations for bone
reparation and we have not re-examined again non-selected/unsorted
bone marrow stromal cells given our existing published data and, im-
portantly, to address the important principles surrounding 3Rs animal
experimentation of replacement, refinement and reduction.
The use of large animal models in pre-clinical translation continues
to present a necessary yet challenging step in the development of novel
therapeutics. However, testing these new therapies from the bench to
large in vivo animal models is not without out its complications parti-
cularly using a multifaceted approach as described in the current study.
Thus, cell scale up using Stro-4+ oBMSCs, matrix hydrogel and melt
electro-written micro-fibre mPCL scaffold generation provided chal-
lenges for the sheep tibial defect model. Our results demonstrated a
non-significant level of bone forming activity compared to controls.
This may be due to a number of components including i) the length of
the study, insufficient to generate new bone or, with the hydrogel
production, ii) nutrient supply and modulated Stro-4 survival over time
and, iii) Limited regeneration of the vasculature with the formation of
new bone, in such a large ovine defect, may all be contributory factors
in the limited regeneration of such a large osseous defect. Although, the
current studies do not support a strong role for Stro-4 cells in the
support of bone formation, it cannot be excluded that an insufficient
number of cells survived across the implantation time frame to support
bone reparation. The manufacture of large volumes of ECM gel (100
fold greater volumes than required for CAM models), development of a
homogenous buffered gel proved challenging and may have led to
discrete regions of variable pH that were difficult to neutralise, subse-
quently affecting skeletal cell activity.
The central role of the mPCL scaffold in the current study was to
localise the bECM hydrogel, permit nutrient diffusion and facilitate
vascular penetration. Melt electro-written micro-fibre mPCL scaffolds
have been produced and characterised in vitro [29,55,56] and utilised
successfully in vivo [57,58]. Previous applications documented the
successful use of a mPCL scaffold fabricated via fused deposition
modelling technology to improve the localisation of incorporated au-
tograft and platelet rich plasma in combination with BMP-7 [59]. So-
lution electrospinning technology was also used to produce fibrous PCL
scaffolds, which localised a cross-linked alginate hydrogel containing
BMP-2 [60]. Autograft was an effective positive control, with sig-
nificant bridging of the defect observed. The use of the mPCL scaffold
membrane on a modest scale, as demonstrated in the successful CAM
model, corroborated applications previously reported [55,59,60]. In
comparison, the use of mPCL scaffold for gel localisation in a large
animal critical-sized defect may not have successfully localised the
biomaterial for a duration sufficient to stimulate osteogenesis. It is not
known whether a failure to localise in an ambulatory large animal was
a contributing factor, gel at the time of application in surgery was well
contained and the construct sound.
Interestingly, in the current studies, Stro-4 oBMSCs displayed a
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propensity to differentiate along the chondrogenic lineage and suggests
an impact on osteogenesis within the implanted Stro-4+ cells/hy-
drogel. In addition, the lack of cell proliferation observed and minimal
vascular response, in marked contrast to the chick CAM vascular-rich
environment, may infer that to orchestrate a reparative response in a
large defect model, the rapid development of the vasculature to the site,
as indicated above, is critical for success.
The question of autologous, allogenic and xenogenic material and
potential deleterious effects on repair warrants consideration. An in-
ability of bovine origin ECM hydrogel to stimulate an osteogenic effect
could relate to the xenogenic nature of the primary tissue. In an acute
inflammatory response, the release of pro-inflammatory cytokines such
as IL-1, IL-2 and TNFα could modulate the pro-osteogenic signalling
derived from matrix bound growth factors such as the TGF-β and BMP-
2. Indeed, the presence of a fibrous cellular capsule around the cell-
seeded and unseeded groups would support an inflammatory interac-
tion. The use of cancellous bovine xenograft has been reported clini-
cally in tibial fracture repair [61], maxillofacial reconstruction [62] and
reconstructive foot surgery [63]. Although widely used and with re-
ported improved efficacy over other common bone graft substitutes
experimentally [64], the efficacy and suitability of xenograft in ortho-
paedics remains an area of considerable debate [65].
A review of ECM xenograft materials failed to identify a reliable
description of the human immune response to xenogenic ECM grafts
[66]. Importantly, when examining a xenograft related immunogenic
response in an ovine model, work by Katz et al., [67] showed com-
parable osteogenesis between decellularised xenograft and allograft.
The immunogenicity of connective tissue grafts has been linked to the
cellular component of the graft tissues. Decellularisation and delivery of
an acellular graft material has been shown to reduce and even remove
the immune response of the host to donor material [65]. Using hy-
drogels as a cell delivery vehicle has been implicated in generating an
enhanced immune response, this was primarily linked to the adsorption
of cell proteins and presentation to host immunocytes [68].
10. Conclusions
The current studies have documented the in vitro and in vivo phe-
notype and function of an enriched skeletal stem cell population se-
lected using the monoclonal IgG Stro-4 antibody and efficacy for bone
formation using a novel mPCL scaffold ECM hydrogel system. oBMSCs
demonstrated evidence of an in vitro growth profile comparable with
human skeletal stem cells. A clear preference for ovine unselected and
Stro-4+ oBMSCs to differentiate along the chondrogenic lineage was
observed, an observation noted in the CAM chick femur defect model
where the vascularised rich environment enhanced the bone repair
when Stro-4+ cells in combination with bone-derived ECM hydrogels
were applied. In a large bone defect model, the propensity of Stro-4+
cells to align to a chondrogenic lineage may have delayed the onset of
the fracture repair. In addition, the deficiency of a functional blood
supply to the ovine defect model would have certainly reduce the re-
generative capacity of the composite-Stro-4+ cells, ECM and sleeve.
The current studies highlight discrete differences between Stro-1 and
Stro-4 skeletal populations with an innate chondrogenic lineage pre-
ference in comparison to published observations for osteogenesis in
Stro-1 enriched adult human cells. The results validate the use of Stro-
4+ skeletal populations and pave the way for in vivo evaluation of
skeletal populations in tissue engineering and regenerative medicine,
but other mitigating factors such as mechanics, vascularisation need to
be incorporated to large scale up fracture models for these skeletal
progenitor cells function at the optimum conditions. Finally, the current
studies indicate the issues around translation from in vitro and small
animal models to predict surgically-relevant efficacy and the challenges
and unreliability that can be observed. It is clear, in the context of large
scale skeletal tissue engineering, a targeted nature is required to meet
the important issues around Reduce, Refine and Replacement for
animal use in translational research. Ongoing studies are focussed on
the translational potential of Stro-4+ oBMSCs and our scaffolds in a
translational model of bone tissue engineering examining cell delivery,
cell concentration and the potential of osteogenic pre-conditioning
prior to implantation for clinical translation. The development of ske-
letal cell selection strategies in combination with deliverable compo-
sites and hydrogels in preclinical translational models auger well for the
generation of hard and soft tissues for the ageing population.
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